Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

10/15/24 4:05:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $EXEL alert in real time by email

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –

Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2024 financial results will be released on Tuesday, October 29, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website.

To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A webcast replay of the conference call will also be archived on www.exelixis.com for one year.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241015906059/en/

Get the next $EXEL alert in real time by email

Recent Analyst Ratings for

$EXEL

Date	Price Target	Rating	Analyst
10/16/2024	$30.00 → $34.00	Outperform	RBC Capital Mkts
9/19/2024	$30.00	Neutral	UBS
4/11/2024	$25.00	Overweight → Equal Weight	Barclays
12/19/2023	$27.00	Buy	BTIG Research
12/15/2023	$31.00	Buy	Citigroup
9/26/2023	$28.00	Buy	H.C. Wainwright
8/22/2023	$25.00 → $29.00	Outperform	Oppenheimer
8/8/2023	$18.00	Market Perform	SVB Securities

More analyst ratings

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Chat with this insight

Recent Analyst Ratings for $EXEL

$EXEL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP and CFO Senner Christopher J. covered exercise/tax liability with 17,506 shares, decreasing direct ownership by 2% to 704,174 units (SEC Form 4)

President and CEO Morrissey Michael covered exercise/tax liability with 47,642 shares, decreasing direct ownership by 5% to 916,742 units (SEC Form 4)

EVP & General Counsel Hessekiel Jeffrey covered exercise/tax liability with 14,672 shares, decreasing direct ownership by 3% to 515,653 units (SEC Form 4)

$EXEL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Johnson David Edward bought $8,733,955 worth of shares (425,000 units at $20.55) (SEC Form 4)

Johnson David Edward bought $3,932,734 worth of shares (190,000 units at $20.70) (SEC Form 4)

Johnson David Edward sold $2,602,038 worth of shares (120,409 units at $21.61) and bought $2,602,038 worth of shares (120,409 units at $21.61) (SEC Form 4)

$EXEL Leadership Updates

Live Leadership Updates

$EXEL Press Releases

Fastest customizable press release news feed in the world

$EXEL FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$EXEL SEC Filings

$EXEL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$EXEL Large Ownership Changes

This live feed shows all institutional transactions in real time.

ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update